News

Article

December 15, 2023

AJMC® in the Press, December 15, 2023

Author(s):

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A study entitled, “Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes,” to be published in the December 2023 issue of The American Journal of Managed Care^® (AJMC^®), was referenced in articles from US News & World Report, Medpage Today, Medical News Today, Healio, HealthDay, and Medical Economics^®. The study found that approximately 40% of patients with type 2 diabetes discontinued their second-line therapies within a year.

An article from Medriva referenced an article published on AJMC.com, the website of AJMC. The article, “Health Insurance Markets Remain Highly Concentrated in the Majority of US,” covered a report from the American Medical Association that found the market for health insurance, both commercial and Medicare Advantage, became more concentrated from 2014 to 2022.

Related Videos

JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)

Marla Black Morgan, MD, Phoebe Neurology Associates

Elizabeth Grush, MBA

Raj Chovatiya, MD, PhD, MSCI.

1 expert in this video

Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center

Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)

Erin Weber, MS

Beau Raymond, MD

Lynae Darbes, PhD

Related Content

"Overactive bladder" written on sticky note | Image Credit: syahrir - stock.adobe.com

April 15th 2025

Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk

Brooke McCormick

Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

Hospital and ED use were similar at the individual and neighborhood levels, but the use of outpatient services differed. | Image credit: Spiroview Inc - stock.adobe.com

April 15th 2025

Individual, Neighborhood-Level Social Risk Indicators Provide Distinct Health Care Use Insights

While findings around hospital and emergency department use were similar at the individual and neighborhood levels, the use of outpatient services differed.

Managed Care Cast Presents: Unlocking the Potential of CGM Technology

April 10th 2025

Managed Care Cast Presents: Unlocking the Potential of CGM Technology

Laura Joszt, MA

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative potential in managing the disease.

Pharmacy online_evso - adobe.stock.com

April 15th 2025

SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps

Giuliana Grossi

Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com

April 15th 2025

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

Jared Kaltwasser

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

Related Content

"Overactive bladder" written on sticky note | Image Credit: syahrir - stock.adobe.com

April 15th 2025

Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk

Brooke McCormick

Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

Hospital and ED use were similar at the individual and neighborhood levels, but the use of outpatient services differed. | Image credit: Spiroview Inc - stock.adobe.com

April 15th 2025

Individual, Neighborhood-Level Social Risk Indicators Provide Distinct Health Care Use Insights

While findings around hospital and emergency department use were similar at the individual and neighborhood levels, the use of outpatient services differed.

Managed Care Cast Presents: Unlocking the Potential of CGM Technology

April 10th 2025

Managed Care Cast Presents: Unlocking the Potential of CGM Technology

Laura Joszt, MA

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative potential in managing the disease.

Pharmacy online_evso - adobe.stock.com

April 15th 2025

SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps

Giuliana Grossi

Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com

April 15th 2025

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

Jared Kaltwasser

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions